Log In
BCIQ
Print this Print this
 

KP415

  Manage Alerts
Collapse Summary General Information
Company KemPharm Inc.
DescriptionProdrug of methylphenidate and a ligand
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentIND
Standard IndicationAttention deficit hyperactivity disorder (ADHD)
Indication DetailsTreat attention deficit hyperactivity disorder (ADHD)
Regulatory Designation
PartnerMonoSol Rx LLC

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/02/2011

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today